Positron Emission Tomography Market Growth Driven by Advanced Molecular Imaging

Positron Emission Tomography Market

The global positron emission tomography market is witnessing steady growth due to increasing demand for advanced molecular imaging, rising prevalence of cancer and neurological disorders, and continuous advancements in PET imaging technologies. The global positron emission tomography market size is estimated at USD 2.01 billion in 2025 and is projected to reach USD 3.22 billion by 2034, growing at a CAGR of 5.45% during the forecast period (2026–2034).

Positron emission tomography (PET) is a highly advanced nuclear imaging technique that enables physicians to visualize metabolic and physiological processes within the human body. PET imaging plays a vital role in oncology, cardiology, neurology, and drug development by supporting early disease detection, accurate diagnosis, treatment planning, and therapy monitoring. The increasing clinical integration of dynamic PET kinetic modeling, which enables quantitative assessment of tracer metabolism for drug response monitoring and early treatment optimization, is significantly contributing to market expansion.

For detailed market insights, growth forecasts, and competitive analysis, visit:

https://straitsresearch.com/report/positron-emission-tomography-market

Market Drivers

Rising Prevalence of Cancer and Neurological Disorders

The growing incidence of cancer, Alzheimer's disease, Parkinson's disease, epilepsy, and cardiovascular disorders is driving demand for advanced diagnostic imaging technologies. PET imaging provides highly accurate metabolic information that supports early diagnosis and personalized treatment planning.

Healthcare providers are increasingly adopting PET systems to improve diagnostic precision and patient outcomes.

Growing Adoption of Dynamic PET Kinetic Modeling

Dynamic PET kinetic modeling enables clinicians to quantify tracer uptake and metabolic activity, improving treatment response assessment and therapy optimization. This technology is becoming increasingly valuable in oncology drug development, precision medicine, and clinical research.

Advanced quantitative imaging continues expanding the clinical applications of PET technology.

Technological Advancements in Hybrid Imaging

The integration of PET with computed tomography (PET/CT) and magnetic resonance imaging (PET/MRI) has significantly improved diagnostic accuracy by combining functional and anatomical imaging. Artificial intelligence and advanced image reconstruction technologies further enhance image quality while reducing scan times.

Continuous innovation is strengthening the role of PET imaging across multiple medical specialties.

Market Challenges

High Equipment and Installation Costs

PET imaging systems require substantial investment in imaging equipment, cyclotrons, radiopharmaceutical production facilities, and specialized infrastructure. These high costs may limit adoption, particularly in developing regions.

Healthcare providers continue seeking cost-effective imaging solutions while expanding diagnostic capabilities.

Limited Availability of Radiopharmaceuticals

PET imaging depends on radioactive tracers with short half-lives that require specialized production and transportation infrastructure. Limited availability of radiopharmaceuticals can affect access to PET imaging services in certain regions.

Ongoing investments in radiopharmaceutical manufacturing are improving supply chain reliability.

Market Segmentation

By Product

The market is segmented into PET scanners, PET/CT systems, PET/MRI systems, radiopharmaceuticals, and related software solutions. PET/CT systems account for the largest market share due to their superior diagnostic capabilities and widespread adoption in oncology imaging.

PET/MRI systems are expected to witness increasing adoption for neurological and cardiovascular applications.

By Application

The market includes oncology, cardiology, neurology, infectious diseases, drug discovery, and research applications. Oncology remains the largest application segment owing to the increasing use of PET imaging for cancer detection, staging, treatment monitoring, and recurrence assessment.

Neurology continues witnessing strong growth with increasing diagnosis of neurodegenerative disorders.

By End User

Major end users include hospitals, diagnostic imaging centers, academic research institutes, cancer centers, and pharmaceutical companies. Hospitals account for the largest market share due to expanding investments in advanced diagnostic imaging infrastructure.

Cancer centers continue increasing adoption of PET imaging for precision oncology.

Regional Insights

North America

North America dominates the positron emission tomography market due to advanced healthcare infrastructure, widespread adoption of molecular imaging technologies, strong reimbursement systems, and significant investments in cancer diagnostics. The United States remains the largest regional market.

Europe

Europe represents a major market supported by expanding healthcare expenditure, increasing adoption of hybrid imaging systems, and growing clinical research activities. Germany, France, the United Kingdom, Italy, and Switzerland remain key contributors.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period. Rising healthcare investments, increasing cancer incidence, expanding diagnostic imaging infrastructure, and growing awareness of early disease detection are driving demand across China, India, Japan, South Korea, and Southeast Asia.

Government initiatives supporting precision medicine continue accelerating regional growth.

Latin America, Middle East & Africa

These regions are gradually improving access to advanced diagnostic imaging through healthcare modernization, infrastructure development, and increased investments in nuclear medicine. Growing healthcare demand is expected to create future market opportunities.

Key Players Analysis

The positron emission tomography market is highly competitive, with leading companies focusing on advanced PET imaging systems, AI-assisted image analysis, radiopharmaceutical innovation, and hybrid imaging technologies. Companies continue investing in research and development, strategic collaborations, and product innovation to strengthen their competitive positions.

The integration of artificial intelligence, digital imaging, and quantitative PET analysis is expected to define the next generation of molecular imaging.

Key Companies

• Siemens Healthineers AG

• GE HealthCare

• Koninklijke Philips N.V.

• Canon Medical Systems Corporation

• Shimadzu Corporation

• United Imaging Healthcare Co., Ltd.

• Bruker Corporation

• Jubilant Radiopharma

• Cardinal Health, Inc.

• Curium Pharma

Conclusion

The global positron emission tomography market is expected to witness steady growth through 2034, driven by increasing adoption of molecular imaging, expanding applications in oncology and neurology, and continuous technological advancements in PET imaging systems. Although high equipment costs and radiopharmaceutical availability remain key challenges, innovations in dynamic PET kinetic modeling, AI-powered imaging, and hybrid diagnostic technologies are expected to create significant growth opportunities. As precision medicine continues to advance, positron emission tomography will remain an essential tool for early diagnosis, treatment monitoring, and personalized patient care.

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: [email protected]

Tel: +1 646 905 0080 (U.S.)

Tel: +44 203 695 0070 (U.K.)